Characterization of efflux pump channel of florfenicol for resistance-enhancing variant RE-CmeABC in Campylobacter
Journal of Antimicrobial Chemotherapy · 2026-03-04 · 81 (4)
DOI: 10.1093/jac/dkag047 ↗Abstract
Abstract Objectives This study aims to elucidate the molecular mechanism of enhanced florfenicol resistance mediated by the resistance-enhanced RE-CmeABC in Campylobacter, with a focus on the evolution of its efflux function. Materials and methods The complex models of FFC with wild-type CmeB and RE-CmeB are constructed by molecular modelling methods, and the efflux channels and corresponding bottleneck residues are predicted by CAVER program. Then mutants are constructed on the basis of predicted amino acid residues by natural transformation and functional confirmation is performed by antimicrobial susceptibility testing and accumulation assay. Results Channel P1 is identified as the optimal FFC efflux channel, and the specific residues composed are illustrated. The corresponding bottleneck residues are S615, S616, Q87, T614, K89, S47 and S84. Among them, mutations of Q87 and K89 are non-conserved, having a particularly pronounced effect on efflux function. Decreased (8-fold) MIC and increased FFC accumulation were observed in MU-11168-RE-CmeABC (with mutated RE-CmeB) compared with that in 11168-RE-CmeABC (with RE-CmeB), respectively, which verifies the predicted FFC efflux tunnel is reliable. This demonstrates that the P1 channel in RE-CmeB has evolved into a dominant and specialized extrusion pathway with minimal functional redundancy, fundamentally underpinning its enhanced resistance. Conclusions Our findings reveal that the enhanced resistance is primarily due to a functional specialization of the P1 efflux channel in RE-CmeB. This elucidation, strongly supported by the concordance between computational predictions and experimental data, provides a mechanistic basis and high-value targets (Q87/K89) for the development of efflux pump inhibitors against multidrug-resistant Campylobacter.
EUVIMED